<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625361</url>
  </required_header>
  <id_info>
    <org_study_id>HEC122505-P-01/CRC-C2017</org_study_id>
    <nct_id>NCT04625361</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects</brief_title>
  <official_title>A Single Center, Randomized, Double-Blind, Placebo-Controlled Study of Single/Multiple Ascending Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Single Center, Randomized, Double-Blind, Two Periods, Crossover, Food Effect Study of HEC122505MsOH Tablets in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in&#xD;
      Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Adverse Events (AEs)</measure>
    <time_frame>Part 1：up to 6 days; Part 2: up to 13 days.</time_frame>
    <description>To investigate the safety and tolerability of HEC122505MsOH by assessment of AEs (non-serious and serious) following administration of oral HEC122505MsOH tablets</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Maximum Plasma Concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Area Under the Curve(AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax Tmax</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Maximum Peak Time(Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Elimination Half-life(t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Mean Residence Time(MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Apparent Clearance(CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Apparent Volume of Distribution(Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Elimination Rate Constant(Kel)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MAO-B</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Monoamine Oxidase B（MAO-B）</description>
  </other_outcome>
  <other_outcome>
    <measure>MAO-A</measure>
    <time_frame>up to 120 hours</time_frame>
    <description>Monoamine Oxidase A（MAO-A）</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（pilot trial arm）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of tablets HEC122505MsOH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC122505MsOH or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC122505MsOH</intervention_name>
    <description>Part2：Mulltiple doses once daily, up to 8 days</description>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）</arm_group_label>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）</arm_group_label>
    <arm_group_label>Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）</arm_group_label>
    <arm_group_label>Single dose of HEC122505MsOH Tablets（pilot trial arm）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing and are able to provide a written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout&#xD;
             the trial.&#xD;
&#xD;
          3. Subjects aged between 18 and 45 (both inclusive) years old.&#xD;
&#xD;
          4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body&#xD;
             mass index ≥18 and ≤28 kg/m2 at screening.&#xD;
&#xD;
          5. Subjects, who are healthy, as having no clinically significant abnormalities in vital&#xD;
             signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a positive serology for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies and/or TP&#xD;
             antibodies at screening.&#xD;
&#xD;
          2. Patients with the following diseases of clinical significance, including but not&#xD;
             limited to those with gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor,&#xD;
             lung, immune, mental, or cardiovascular and cerebrovascular diseases.&#xD;
&#xD;
          3. nown allergic reactions or hypersensitivity to any excipient of the drug&#xD;
             formulation(s)， anaphylaxis physique.&#xD;
&#xD;
          4. Use of any prescription or non-prescription medications within 14 days prior to&#xD;
             initial dosing，Use of any drugs that inhibit or induce liver metabolism within 28 days&#xD;
             before the first dose, or use of any of the following drugs within 28 days before the&#xD;
             first dose: monoamine oxidase inhibitors, opioids, serotonergic drugs, sympathetic&#xD;
             nerves Drugs, breast cancer resistance protein substrates, dopaminergic antagonists,&#xD;
             etc.&#xD;
&#xD;
          5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit&#xD;
             within 48 hours prior to initial dosing.&#xD;
&#xD;
          6. Positive results from urine drug screen test.&#xD;
&#xD;
          7. History of alcoholism or drink regularly within 3 months prior to the study (defined&#xD;
             as Alcohol consumption of &gt; 21 units/week), or positive results from alcohol breath&#xD;
             test.&#xD;
&#xD;
          8. Regular smoking of more than 10 cigarettes per day within 3 months before&#xD;
             administration of study drug, or inability to refrain from smoking during the course&#xD;
             of the study.&#xD;
&#xD;
          9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.&#xD;
&#xD;
         10. Subjects who plan to receive or have had organ transplants.&#xD;
&#xD;
         11. Females who are lactating/breastfeeding, or positive result from pregnancy test for&#xD;
             women of child-bearing potential.&#xD;
&#xD;
         12. Subjects who participated in another clinical trial within 3 months prior to initial&#xD;
             dosing.&#xD;
&#xD;
         13. Any other condition with in the opinion of the investigator would render the patient&#xD;
             unsuitable for inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanmei Liu, MS</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanMei Liu, MS</last_name>
      <phone>021-54030254</phone>
      <email>ymliu@shxh-centerlab.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

